Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: J Hepatol. 2010 Nov 23;55(1):76–85. doi: 10.1016/j.jhep.2010.10.033

Figure 1.

Figure 1

Figure 1

PEG-IFN adherence among participants with A) HCV receiving PEG-IFN alone in the ATAHC study (n=74). B) HCV/HIV receiving PEG-IFN and ribavirin in the ATAHC study (n=35). Black boxes represent dose received, grey boxes - dose-reductions and blank boxes - no dose received. SVR, sustained virologic response; Y, yes; N, no.